Capital Investment Advisors LLC cut its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 8.2% in the 2nd quarter, HoldingsChannel reports. The firm owned 9,033 shares of the financial services provider’s stock after selling 804 shares during the period. Capital Investment Advisors LLC’s holdings in iShares Biotechnology ETF were worth $1,143,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Ramirez Asset Management Inc. purchased a new position in iShares Biotechnology ETF in the first quarter worth $26,000. Financial Gravity Asset Management Inc. purchased a new stake in iShares Biotechnology ETF during the first quarter valued at about $30,000. Woodside Wealth Management LLC bought a new stake in iShares Biotechnology ETF during the first quarter worth about $31,000. CX Institutional purchased a new position in shares of iShares Biotechnology ETF in the 1st quarter worth about $32,000. Finally, Garde Capital Inc. bought a new position in shares of iShares Biotechnology ETF during the 1st quarter valued at about $36,000. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Price Performance
Shares of NASDAQ IBB opened at $148.51 on Thursday. The stock’s 50-day moving average is $138.59 and its 200 day moving average is $129.79. iShares Biotechnology ETF has a 1-year low of $107.43 and a 1-year high of $150.04.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- What Are Dividends? Buy the Best Dividend Stocks
- Datavault AI: The New AI Contender Backed by Big Funding
- How to Capture the Benefits of Dividend Increases
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- What is the Dow Jones Industrial Average (DJIA)?
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.